Small Ball Wins Games – Combination Therapy for Goal Attainment
J.A. Randy Englert, MD, FACC
Matthew Malachowski, Pharm. D., MHA
Extra Innings – Sustaining Victory Beyond the First Game
Crossing Home Plate – Building a Winning Team Culture
Translating the Latest KDIGO Guidelines Into Practice: IV Iron Therapy in Patients With Non–Dialysis-Dependent CKD
Patrick Rossignol, MD, PhD
Julio Núñez, MD, PhD
Optimizing Iron Deficiency Management in CKD: IV Iron Replacement Therapy Amid the Latest KDIGO Guidelines
Brendon Neuen, MBBS, PhD
Vous prescrivez uniquement des antihistaminiques pour traiter les patients atteints de Pa-MRC ? Il est temps de revoir votre approche !
Antoine Lanot, MD, PhD
Gil Yosipovitch, MD
Transforming Care in Pediatric Patients With C3 Glomerulopathy: Targeting C3 at the Source
Richard Lafayette, MD, FACP
Ankana Daga, MD
Stuck on Antihistamines for Managing Patients With CKD-aP? Time to Reconsider!
Hypertrophic Cardiomyopathy: Moving From Monitoring to Action in the Era of Myosin Inhibitors
Joseph Rossano, MD
Hypertrophic Cardiomyopathy: Overcoming Practical Barriers to Treatment in the Era of Myosin Inhibitors
Florian Rader, MD
Safety in oHCM Therapy: How and When to Transition Treatment?
Anjali Owens, MD
Modern Obstructive HCM Care: From Unmet Needs to Individualized Myosin Inhibitor Therapy
Ahmad Masri, MD, MS
Michael Nassif, MD, MSc
Cracking the Code of Obstruction: Unmet Needs in oHCM
When ß-Blockers Fall Short in oHCM: Time for a New Approach?
Individualized Management of Hyperkalemia: The Role of Potassium Binders in Patients With Cardiorenal Disease
Ellie Kelepouris, MD, FACP, FAHA
The Patient-Clinician Connection in Managing CKD-aP
James Burton, DM, FRCP
Lucio Manenti, MD, PhD